The tri-specific antibody PIT565 targeting CD3 × CD2 × CD19 is currently being tested as a monotherapy, as an IV or SC formulation in R/R B-NHL and R/R B-ALL (NCT05397496). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.